STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its ...
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, with a commercial ...
A new study has reported the effectiveness of raising glutathione levels in the blood through oral supplementation of liposomal glutathione. However, the team at Inid Research Labs that developed the ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Objective: Divalproex extended release (ER) tablets have lower bioavailability than conventional divalproex tablets. Objectives were to provide dose-increment justification for conversion of a patient ...
Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). Methods: In this randomized, ...
Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Indirect treatment comparison of ...
Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma ...
Divalproex is available as 125, 250 and 500mg tablets. Therefore, the possible divalproex total daily dosage regimens are in increments of 125mg. Table IV shows that all divalproex dosage regimens, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results